Abstract
Breast cancer is a disease that has plagued many women globally. The rapid rise in the incidence rate has prompted the rigorous search to understand its etiology and find better management strategies for this disease. Metallothionein (MT) belongs to a family of metal-binding proteins where dysregulated expression of this protein has been observed in invasive breast ductal carcinomas. Since its discovery in equine kidney, functions of MT have extended beyond the initial role of heavy metal detoxification to promoting tumorigenesis. MT, which was reported to be highly expressed in many tumors including breast cancers, is known to regulate key processes such as cell proliferation, apoptosis and even chemoresistance. In this patent review, we shall evaluate the roles of 10 functional isoforms of MT in breast neoplasia and discuss the utility of MT isoforms as biomarkers for prognosis. Strategies targeting MT for treatment could provide alternatives to overcome this dreaded disease which has claimed the lives of many women.
Keywords: Biomarker, breast cancer, chemoresistance, metallothionein, molecular therapy, MT-1E, MT-2A, MT-3, tumorigenesis, mammary gland
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting Metallothionein for Prognosis and Treatment of Breast Cancer
Volume: 6 Issue: 2
Author(s): Yiyang Lai, George W.-C. Yip and Boon-Huat Bay
Affiliation:
Keywords: Biomarker, breast cancer, chemoresistance, metallothionein, molecular therapy, MT-1E, MT-2A, MT-3, tumorigenesis, mammary gland
Abstract: Breast cancer is a disease that has plagued many women globally. The rapid rise in the incidence rate has prompted the rigorous search to understand its etiology and find better management strategies for this disease. Metallothionein (MT) belongs to a family of metal-binding proteins where dysregulated expression of this protein has been observed in invasive breast ductal carcinomas. Since its discovery in equine kidney, functions of MT have extended beyond the initial role of heavy metal detoxification to promoting tumorigenesis. MT, which was reported to be highly expressed in many tumors including breast cancers, is known to regulate key processes such as cell proliferation, apoptosis and even chemoresistance. In this patent review, we shall evaluate the roles of 10 functional isoforms of MT in breast neoplasia and discuss the utility of MT isoforms as biomarkers for prognosis. Strategies targeting MT for treatment could provide alternatives to overcome this dreaded disease which has claimed the lives of many women.
Export Options
About this article
Cite this article as:
Lai Yiyang, W.-C. Yip George and Bay Boon-Huat, Targeting Metallothionein for Prognosis and Treatment of Breast Cancer, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489211795328495
DOI https://dx.doi.org/10.2174/157489211795328495 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
γ-Hydroxybutenolide Containing Marine Natural Products and Their Synthesis: A Review
Current Organic Chemistry Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Recent Advances in the Rational Drug Design Based on Multi-target Ligands
Current Medicinal Chemistry Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Current Clinical Pharmacology Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Identification of High Affinity Bioactive Salbutamol Conformer Directed Against Mutated (Thr164Ile) Beta 2 Adrenergic Receptor
Current Topics in Medicinal Chemistry Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine CD26: A Multi-Purpose Pharmacological Target
Current Clinical Pharmacology New Platinum (II) Ternary Complexes of Formamidine and Pyrophosphate: Synthesis, Characterization and DFT Calculations and <i>In vitro</i> Cytotoxicity
Combinatorial Chemistry & High Throughput Screening microRNAs: Small Molecules with a Potentially Role in Oral Squamous Cell Carcinoma
Current Pharmaceutical Design Alpha-Helical Cationic Anticancer Peptides: A Promising Candidate for Novel Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Inhibition of Human Aromatase by Myosmine
Drug Metabolism Letters PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets GnRH-Analogues for Ovarian Protection in Childhood Cancer Patients: How Adult Hypotheses are Relevant in Prepubertal Females
Current Drug Targets Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?
Current Angiogenesis (Discontinued)